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A B S T R A C T
The aims of this study were to investigate experienced stigma and discrimination and their associated factors in
people with schizophrenia who live in the community in Guangzhou, China. A total of 384 people with schi-
zophrenia were randomly recruited from four districts of Guangzhou and completed the scales and ques-
tionnaires: Internalized Stigma of Mental Illness scale (ISMI), Self-Esteem Scale (SES), Discrimination and Stigma
Scale (DISC-12), Brief Psychiatric Rating Scale (BPRS), PANSS negative scale (PANSS-N), Global Assessment of
Functioning (GAF) and Schizophrenia Quality of Life Scale (SQLS). Insight and medication compliance were
evaluated by psychiatrists. Data were analyzed by using descriptive statistics, Pearson correlation and multi-
variable linear regression. We found a signiﬁcant positive correlation between BPRS score and PANSS-N score,
GAF score was signiﬁcantly negative correlated with SQLS score, Insight score was signiﬁcantly negative cor-
related with medication compliance score, ISMI score was signiﬁcantly positive correlated with SES score and
experienced discrimination score. Multivariable linear regression found SQLS, SES and experienced dis-
crimination were the main independent variables of ISMI and experienced discrimination was the most im-
portant factor of ISMI. Our ﬁndings suggest that people with schizophrenia often experienced stigma and dis-
crimination in this Chinese population, and more anti-stigma interventions should be provided.
1. Introduction
Schizophrenia is a serious and highly stigmatized mental disorder
(Link et al., 2006; Sharaf et al., 2012). People with schizophrenia are
often incorrectly thought to be more dangerous, aggressive and prone
to crime (Yılmaz et al., 2015). The condition has a profound eﬀect on
the individuals aﬀected, for example, high rates of unemployment and a
reduced life expectancy of around 10–20 years (Owen et al., 2016).
Schizophrenia accounts for 7.4% of global disability-adjusted life years
(DALYs) reported in the 2010 Global Burden of Disease Study (Patel
et al., 2014). Stigma and discrimination are complicating features of
psychiatric disorders and treatment, especially for schizophrenia.
Stigma was ﬁrst deﬁned as “an attribute that is deeply discrediting”
(Semrau et al., 2015); however, this concept received criticism for
being too individually focused and loosely deﬁned. Recently, it is
documented that stigma contains labeling, stereotyping, separation,
status loss, and discrimination (Link et al., 2001; Omori et al., 2014).
Moreover, Corrigan categorized stigma as public stigma and self-stigma
(Brohan et al., 2010b). Stigma has been deﬁned as comprising three
elements: problems of knowledge (ignorance or misinformation), pro-
blems of attitudes (prejudice), and problems of behaviour (dis-
crimination) (Brohan et al., 2010b; Mosanya et al., 2014; Thornicroft
et al., 2007). This conceptualisation provides a new direction focusing
on how discrimination is experienced and establishing an evidence base
of eﬀective interventions.
Stigma and discrimination have been associated with poor quality of
life, low self-esteem, and social withdrawal in people with schizo-
phrenia (Brohan et al., 2011; Rusch et al., 2005). As a result, people
with schizophrenia often try to hide their illness or stop themselves
from taking on opportunities (Koschorke et al., 2014). Discrimination
also disadvantages individuals in several ways, such as unemployment,
loss of income, reduced access to education, housing or health care
(Thornicroft et al., 2016; Yin et al., 2014). Patients with schizophrenia
may have less investment of health-care resources allocated than those
http://dx.doi.org/10.1016/j.psychres.2017.05.040
Received 6 February 2017; Received in revised form 14 April 2017; Accepted 27 May 2017
⁎ Correspondence to: Guangzhou Huiai Hospital, Guangzhou Medical University, No. 36 Mingxin Road, Liwan District, Guangzhou 510370, China.
E-mail address: biglijie@163.com (J. Li).
Psychiatry Research 255 (2017) 225–231
Available online 29 May 2017
0165-1781/ © 2017 Elsevier B.V. All rights reserved.
MARK
with physical illnesses, and a low use of diagnostic procedures when the
patients have physical illness (Sartorius, 2007). With such a poor health
care, people with schizophrenia might delay or stop seeking treatment
or terminate treatment prematurely. Arguably, sigma and discrimina-
tion are the most important obstacles to the provision of mental health
care and to the development of mental health programs (Beldie et al.,
2012; Sartorius, 2013).
The way people experienced stigma and discrimination may be
diﬀerent because of the diﬀerent cultural contexts (Koschorke et al.,
2014). From the historical perspective, people with mental disorders in
Europe were sometimes thought to be possessed by “evil spirits”, which
may well have been associated with high levels of stigma and dis-
crimination. However, people would receive relatively human treat-
ment in some Muslim societies. The main sources of reported experi-
enced stigma and discrimination recently are from high-income
countries (HICs), displaying high rates of stigma and discrimination in
making friends, job-seeking (Thornicroft et al., 2009), and self-stigma
(Brohan et al., 2010a). For the negative consequences of stigma and
discrimination, schizophrenia has been selected as the central focus of
the World Psychiatric Association's global anti-stigma programme en-
titled “Open the Doors” (Biﬀtu et al., 2014; Stuart, 2008). In order to
deliver primary health-care eﬀectively, HICs have executed community
based programs, which rely on shifting tasks from specialists to non-
specialists (Kakuma et al., 2011).
However, people with mental illness who live in the community
(where services tend to be more established) still experience stigma and
discrimination (Semrau et al., 2011). While there still a lack of studies
in low- and middle-income countries (LMICs), where about 85% of the
world's population live (Jacob et al., 2007). One international study
using population-wide data from 16 countries found even higher rates
of reported stigma among people with mental disorders in developing
(31.2%) than in developed (20%) countries (Alonso et al., 2008).
In China, an estimated 173 million Chinese people have been di-
agnosed with psychiatric disorder, but among them 158 million have
never received any treatment (Xiang et al., 2012). Most studies have
focused on investigation of social stigma in people with schizophrenia
(Lee et al., 2005), and the knowledge and attitudes of medical students
(Rong et al., 2011) or family members (Phillips et al., 2002) toward
patients with mental illness. Few studies have emphasized behaviors
that help people to deal with the stigma and discrimination of mental
illness in LMICs.
Guangzhou is the capital city of Guangdong province, near to Hong
Kong and the adjusted lifetime prevalence rate of mental disorders is
about 15.76% (Zhao et al., 2009). More than 20,000 patients with
schizophrenia are registered in the system of Guangzhou severe mental
disorders management database. Guangzhou Huiai Hospital (also
known as Guangzhou Brain Hospital) has been in charge of manage-
ment of people with mental illness for more than half a century. Several
studies have reported the level of stigma (Li et al., 2014b) and the
knowledge and attitude among community mental health staﬀ (Li et al.,
2014a). However, no assessment about the experiences of stigma,
especially discrimination among people with schizophrenia in com-
munity has been reported.
The aims of this study therefore are to assess the experiences of
stigma and discrimination among individuals with schizophrenia in
community of Guangzhou, China, and to investigate the factors asso-
ciated with a higher likelihood of experiencing stigma and dis-
crimination. Also, we want to emphasize that this study is a part of the
Policy, Training, Services and Assessment (PTSA), also called
“Guangzhou Mental Health Model” (Li et al., 2015), which aims at
overcoming the deﬁciency of the serious human resource shortage and
huge treatment gap, and providing eﬀective community mental health
services in real situations. In this way, the study will provide baseline
information for the further research of interventions.
2. Method
2.1. Study design and participants
The cross-sectional study was conducted at Guangzhou Huiai
Hospital in a sample of patients with schizophrenia, who were regis-
tered in the system of Guangzhou severe mental disorders management
database. More than 50,000 people have been registered in the system,
about 20,000 of whom have a clinical diagnosis of schizophrenia. We
ﬁrst divided the 12 administrative districts in Guangzhou City into 2
clusters (6 central districts and 6 suburban districts) according to their
geographical location. Then we randomly chose two central districts
(Tianhe and Liwan) and two suburban districts (Huadu and Nansha)
from the 2 clusters. The sample size was calculated by the formula (Li
et al., 2015). And then 120 participants from each district were ran-
domly recruited. All participants were screened based on the inclusion
criteria and exclusion criteria described below.
Inclusion criteria included: (1) Participants were diagnosed as
having schizophrenia by certiﬁed psychiatrists according to ICD-10
DCR criteria; (2) Aged between 18 and 50 years old; (3) Participants
had at least full primary school education; (4) Participants were taking
antipsychotic drugs, and had a stable condition; (5) Participants lived in
the local community during the study. Exclusion criteria included: (1)
hospitalized due to substance abuse prior to the study, acute risk of
suicide and violence, severely intellectually challenged with learning
diﬃculties; (2) severe and unstable physical disease such as cere-
brovascular diseases, etc; (3) patients who were pregnant and / or
lactating. A total of 384 patients were enrolled. 96 participants were
excluded, and the main reasons were: (1) though the diagnosis in the
computer system was given as schizophrenia, this was not the clinical
diagnosis given about the project senior psychiatric staﬀ; (2) patients
with serious physical comorbid conditions; or (3) those who did not
consent to participate.
The survey was conducted from April 2015 to July 2015. The study
protocol was approved by Research Ethics Committee of Guangzhou
Huiai Hospital (Number 012, 2015). Written informed consent was
obtained from each participant after the procedure had been fully ex-
plained.
2.2. Measurements
The Brief Psychiatric Rating Scale (BPRS): developed by Overall and
Gorham, was used to assess the severity and change of psychotic and
some depressive symptoms in schizophrenia and other psychotic dis-
orders (Altintas et al., 2016). The scale has been translated into Chinese
and is the most frequently used measure of assessing psychopathology.
It has good validity and inter-rater reliability (Zhang et al., 1983). It
consists of 18 items, each being rated for symptom severity ranging
from 1 (not present) to 7 (extremely severe). Factor analysis results
suggested diﬀerent symptom clusters in this scale: the set of negative
symptoms (emotional withdrawal, blunted aﬀect, and motor retarda-
tion) and the set of positive symptoms (conceptual disorganization,
hallucinations, and unusual thought content). Scores obtained from the
BPRS rating range from 18 to 126. A higher total score represents more
severe psychotic symptoms experienced by the participants.
The Positive and Negative Syndrome Scale for Schizophrenia
(PANSS): developed by Stanley R. Kay, was used to assess positive and
negative symptoms as well as general psychopathology and to measure
the levels of these symptoms in case of schizophrenia or any other
psychotic disorder (Brain et al., 2014). The scale has been translated
into Chinese and has good validity and inter-rater reliability (Si et al.,
2004).
The scale consists of 30 items rated from 0 (absent) to 7 (extreme)
that represent increasing levels of psychopathology. Seven items are
related to positive symptom subscale, seven items are related to nega-
tive symptom subscale, and the remaining 16 items are related to
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general psychopathology subscale. This study only used the negative
symptom subscale. The main reason was that this paper was a baseline
study, our main purpose was to investigate whether the negative
symptoms could be improved after interventions (see another paper
which is in submitting), which was associated with the social function.
And PANSS-N could increase the sensitivity to analysis negative
symptoms. Another reason was the limitation of human resources. A
higher total score represents more serious psychopathology. Insight and
medication compliance were assessed by senior psychiatrists at the
same time. Both insight and medication compliance consist of three
items. The severity of insight was rated from 1 (no insight) to 3
(complete insight). A higher score of insight represents better insight.
The severity of medication compliance rated from 1 (complete medi-
cation compliance) to 3 (no medication compliance). The types of
medication compliance were distinguished as below: complete com-
pliance = takes antipsychotic drugs according to the doctor's advice
completely during the last month; part compliance = takes anti-
psychotic drugs according to the doctor's advice more than 15 days
during the last month; no compliance = takes antipsychotic drugs ac-
cording to the doctor's advice less than 15 days during the last month. A
lower score of medication compliance represents better medication
compliance.
The Global Assessment of Functioning (GAF): developed by the
American Psychiatric Association, was used to assess psychological,
social and occupational functioning in case of schizophrenia or any
other psychotic disorder (Fung et al., 2011). The scale has been trans-
lated into Chinese and has good validity and inter-rater reliability. It is
a single-item questionnaire rated from 0 to 100. A higher score re-
presents better psychological, social and occupational functioning.
The Schizophrenia Quality of Life Scale (SQLS): developed by
Wilkinson, was used to assess patients’ quality of life (Wilkinson et al.,
2000). The scale has been translated into Chinese and has good validity
and inter-rater reliability. The SQLS is a schizophrenia-speciﬁc quality-
of-life instrument that measures quality of life according to the patients’
perspective (Li et al., 2003). The SQLS is a self-administered scale
comprising 30 items. All except four items are scored on a 5-point Likert
scale (0 = never, 1 = rarely, 2 = sometimes, 3 = often, and 4 =
always), with the exceptional four items being reverse-coded, and the
total score is calculated. A lower score represents a better quality of life,
while a higher score indicates a poorer quality of life.
The Internalized Stigma of Mental Illness scale (ISMI): developed by
Ritsher, was used to assess service users’ experience of internalized
stigma (Ritsher et al., 2003). The scale has been translated into Chinese
and has good validity and inter-rater reliability (Li et al., 2009). The
scale consists of 29 items and uses a Likert scale from 1 = strongly
disagree to 4 = strongly agree. This instrument comprises of ﬁve
subscales: alienation, stereotype, discrimination experience, social
withdrawal and stigma resistance. The items of the subscale stigma
resistance are scored in reverse. A higher score of ISMI represents
higher internalized stigma.
The Self-Esteem Scale (SES): developed by Rosenberg, was used to
indicate the degree of patients’ agreement or disagreement with state-
ments about their self-esteem and self-deprecation (Rosenberg et al.,
1978). The scale has been translated into Chinese and has good validity
and inter-rater reliability (Shen et al., 2008). This scale consists of 10
items and uses a Likert scale from 1 = strongly agree to 4 = strongly
disagree. Items are summed into a total score such that a higher score
indicates a lower self-esteem.
The Discrimination and Stigma Scale (DISC-12): developed by
Thornicroft et al., was used to assess the patients' past experiences of
stigma since the ﬁrst appearance of a mental health problem by the
research psychiatrist at the 12 month endpoint visit (Brohan et al.,
2013). The scale has been translated into Chinese and has good validity
and test-retest reliability (Li et al., 2016). The scale consists of 32 items,
four subscales and scores on a 4-point scale from 0 (not at all) to 3 (a
lot). The four DISC-12 subscales are as follows: patient experienced
discrimination (Item 1–21), deﬁned as unfair treatment and unjust
distinction in how diﬀerent people are being treated by others. A higher
score indicates greater experienced discrimination.
Anticipated discrimination (Item 22–25), refers to the extent to
which the patients limit their involvement in important aspects of daily
life, such as intimate relationships and work, because of anticipation
that stigma might occur. A higher score indicates greater limitation in
their daily life. Two items on overcoming stigma (Item 26–27), assess
the coping mechanisms patients use to overcome discrimination. A
higher score indicates more methods know to overcome discrimination.
Positive treatment due to the mental illness (Item 28–32), meaning
reported positive treatment received by others as a result of their
mental illness. A higher positive treatment score indicates more positive
treatment being reported.
2.3. Statistical analysis
Statistical analysis was conducted using IBM SPSS Statistics (version
21.0; IBM Corporation, Armonk, NY, USA). Descriptive statistics in-
cluding the mean, standard deviation (SD), frequency and proportion
were used to summarize the demographics, subscale scores and mean
scores of rating scales. Item-total correlations were calculated with
Pearson correlation coeﬃcient. Multivariable linear regression was
used to assess the association of relative factors with stigma and dis-
crimination. Unadjusted regression coeﬃcients (b), adjusted regression
coeﬃcients (bad) and 95% conﬁdence intervals (95%CI) were calcu-
lated. We adjusted for the following covariates: sex, age, marital status,
education level, number of hospitalization and duration of illness.
Statistical signiﬁcance was set at the level P<0.05.
3. Results
3.1. Socio-demographic characteristics
Social and demographic characteristics of participants are sum-
marized in Table 1. 384 participants with schizophrenia from the
community of Guangzhou were included to this study and all responded
to the survey. Almost all participants reported Han nationality (99%).
197 (51.3%) were males and 187 (48.7%) females. The average age was
39.96 (SD = 7.69) years and average education years 10.13 (SD =
2.60). They had an average duration of illness of 14.54 (SD = 7.97)
years and 2.48 (SD = 3.03) hospitalization times. 198 (51.6%) parti-
cipants were single, 146 (38.0%) married, and 40 (10.4%) others di-
vorced or widowed. Most (n = 272, 70.8%) were unemployed.
Table 1
Social and demographic characteristics.
Characteristics Total group (n = 384)
Age (years) (Mean± SD) 39.96± 7.69
Race (Han) n (%) 380 (99.0)
Sex n (%)
Male 197 (51.3)
Female 187 (48.7)
Marital status n (%)
Single 198 (51.6)
Married 146 (38.0)
Divorce/Widowed 40 (10.4)
Occupation n (%)
Yes 112 (29.2)
No 272 (70.8)
Education level (Mean± SD) 10.13± 2.60
Duration of illness(years) (Mean± SD) 14.54± 7.97
Number of hospitalization (Mean± SD) 2.48±3.03
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3.2. Clinical characteristics and clinical symptoms
Clinical Characteristics of participants are summarized in Table 2.
The mean total score of the BPRS was 27.33 (SD= 7.16), and 17.15 (SD
= 5.40) for the PANSS negative subscale score. Pearson correlation
showed a positive correlation between BPRS total score and PANSS
negative score (r = 0.448, P<0.01).
The medication compliance scale showed that 292 (76%) partici-
pants were fully compliant with prescribed medication, 88 (22.9%)
partial compliance, and 4 (1.0%) no compliance, suggesting that most
of the participants had high medication compliance. In addition, the
insight scale showed that 100 (26%) participants had full insight, 238
(62%) partial insight and 46 (12%) no insight, suggesting that most of
the participants had insight. Pearson correlation showed a negative
correlation between medication compliance score and insight score (r
= −0.356, P<0.01).
3.3. Social function and quality of life with participants
Social Function and Quality of Life in participants are summarized
in Table 2. The mean total scores of the GAF and SQLS were 62.72 (SD
= 11.47) and 31.79 (SD = 15.83), respectively. Mean scores on the
three SQLS subscales were: 30.06 (SD = 19.99) for psychosocial, 46.30
(SD = 16.17) for motivation/energy, and 22.35 (SD = 17.03) for
symptoms/side eﬀects. Pearson correlation showed a negative corre-
lation between GAF total score and SQLS total score (r =−0.129, P =
0.01).
3.4. Stigma and discrimination and self-esteem levels in participants
Stigma and Discrimination and Self-esteem Levels in participants
are summarized in Table 2. Mean scores on the ISMI were: 2.30 (SD =
0.39) for total score, 2.31 (SD = 0.60) for alienation, 1.06 (SD = 0.78)
for stereotype, 2.31 (SD = 0.54) for discrimination experience and 2.34
(SD = 0.53) for social withdrawal and 2.28 (SD = 0.46) for stigma
resistance, indicating internalized stigma in the participants.
Mean scores on the DISC-12 were: 0.20 (SD = 0.27) for Experienced
discrimination, 0.79 (SD = 0.72) for Anticipated discrimination, 0.75
(SD = 0.69) for Overcoming stigma and 0.73 (SD = 0.63) for Positive
treatment. The mean total score of SES was 23.14 (SD = 3.90), sug-
gesting a loss of self-esteem in the participants. Pearson correlation
showed that the ISMI total score was positively correlated with ex-
perienced discrimination (r = 0.294, P<0.01), anticipated dis-
crimination (r = 0.195, P<0.01), and SES total score(r = 0.55,
P<0.01).
3.5. Multivariable linear regression
The results of multivariable linear regression are summarized in
Table 3. Stepwise multiple regression analysis used the ISMI total score
as dependent variable with BPRS, PANSS-N, GAF, SQLS, SES total
scores and four DISC-12 subscales that showed p-value greater than
0.05 in correlation analyses as the independent variables. Covariates in
these stepwise forward entry models included sex, age, marital status,
education level, number of hospitalization and duration of illness. R2 of
the multiple linear regression model was 0.409. The result revealed that
ISMI total score was independently associated with SQLS (bad = 0.007,
P<0.01), SES (bad = 0.032, P<0.01) and experienced discrimination
(bad = 0.141, P<0.05), suggesting that the experienced discrimination
was the factor most signiﬁcantly associated with stigma.
4. Discussion
Stigma and discrimination in mental health are issues of vital im-
portance, since they act as barriers to limit the recognition and treat-
ment of people with ﬁrst-episode psychosis, or to the reduced use of
services and reduced engagement in leisure activities for patients
(Wright et al., 2015). To the best of our knowledge, this is the ﬁrst study
to report the experienced stigma and discrimination in patients with
schizophrenia in local community of Guangzhou, China, which will
provide the possible comparison to those studies from diﬀerent coun-
tries and cultures.
Our study showed that patients with schizophrenia generally ex-
perienced high levels of stigma; however, discrimination experiences
were comparatively less than often described. Our results were not
consistent with the previous studies (Brohan et al., 2010a; Brain et al.,
Table 2
Measurements among participants.
Measurements
BPRS total score (Mean± SD) 27.33± 7.16
PANSS Negative subscale (Mean±SD) 17.15± 5.40
Medication compliance
Complete compliance n (%) 292(76%)
Part compliance n (%) 88(22.9%)
No compliance n (%) 4(1.0%)
Insight
Complete insight n (%) 100(26%)
Part insight n (%) 238(62%)
No insight n (%) 46(12%)
GAF total score (Mean± SD) 62.72± 11.47
SQLS total score (Mean± SD) 31.79± 15.83
Psychosocial 30.06± 19.99
Motivation/energy 46.30± 16.17
Symptoms /side eﬀects 22.35± 17.03
ISMI total score (Mean± SD) 2.30± 0.39
Alienation 2.31± 0.60
Stereotype 1.06± 0.78
Discrimination experience 2.31± 0.54
Social withdrawal 2.34± 0.53
Stigma resistance 2.28± 0.46
DISC-12 subscales (Mean± SD)
Experienced discrimination 0.20± 0.27
Anticipated discrimination 0.79± 0.72
Overcoming stigma 0.75± 0.69
Positive treatment 0.73± 0.63
SES total score (Mean± SD) 23.14± 3.90
Table 3
Multivariate regression coeﬃcients and 95% conﬁdence intervals for the association
between ISMI and other measurements among participants.
Characteristics b (95%CI) bad (95%CI)#
BPRS total score 0.012(0.007–0.018)*** –
PANSS-N 0.007(0.000–0.014) –
GAF total score −0.005(−0.008 to 0.001)** –
SQLS total score 0.013(0.011–0.015)*** 0.007(0.004–0.010)***
SES total score 0.055(0.047–0.064)*** 0.032(0.021–0.042)***
Experienced
discrimination
0.421(0.283–0.559)*** 0.141(0.015–0.268)*
Anticipated
discrimination
0.106(0.052–0.160)*** –
Overcoming stigma −0.024(−0.082 to 0.033) –
Positive treatment 0.011(−0.051 to 0.073) –
Stepwise multiple regression analysis used the ISMI total score as dependent variable with
BPRS, PANSS-N, GAF, SQLS, SES total scores and four DISC-12 subscales that showed p-
value greater than 0.05 in correlation analyses as the independent variables. Covariates in
these stepwise forward entry models included sex, age, marital status, education level,
number of hospitalization and duration of illness. R2 of the multiple linear regression
model was 0.409.
–: Variables were not signiﬁcant after controlling for above characteristics.
* P<0.05.
** P<0.01.
*** P<0.001.
# Adjusted for participants’ sex, age, marital status, number of hospitalization and
duration of illness.
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2014). The possible reasons may be related to the clinical character-
istics of the participants. For example, our participants had been hos-
pitalized for more than two times. Having at least one lifetime psy-
chiatric hospital admission is a strong predictor of illness severity
(Thornicroft et al., 2009). And they had a long duration of illness and
most of them had more than 14 years. Thus, the participants’ situation
may have been exposed to the community and they won’t concern
about discrimination. What's more, responses to questions in the DISC-
12 could also explain this phenomenon. For example, Item 21 in the
subscale of experienced discrimination: Have you been avoided or
shunned by people who know that you have a mental health problem?
106 (28.4%) participants answered yes. That means more than half
participants reported that they had not been avoided or shunned.
However, this pattern of experienced discrimination could be presented
in work-related aﬀairs (Oshodi et al., 2014). In our study, 272 (70.8%)
were unemployed, which is consistent with previous studies, showing a
signiﬁcant impact of discrimination on job-seeking (Daumerie et al.,
2012). Unemployment may be the result of combination of public dis-
crimination and patients’ perceived stigma (Hansson et al., 2014). A
survey of 74 American outpatients diagnosed with schizophrenia found
that 50% of respondents reported that they had “at least sometimes”
been treated as less competent by others, and 42% patients reported
similar frequencies of having been “shunned or avoided” when others
learned of their psychiatric treatment (Yang, 2007). Item 25 in the
subscale of anticipated discrimination: Have you concealed or hidden
your mental health problem from others? 244 (63.5%) participants
answered yes. The explanation of this behavioral pattern could be due
to fear of discrimination, since schizophrenia patients usually prefer to
hide their diagnosis.
Discrimination appears to be a universal phenomenon (Yang et al.,
2007). We consider that the actual rate could be underestimated be-
cause of “face” (also called mianzi). Face is a crucial aspect of social
identity and represents power and standing in the Chinese social hier-
archy. Thus, diagnosis of schizophrenia results in a “loss of face” for the
individual, and having a mental illness is regarded as extremely sha-
meful in Chinese society (Lv et al., 2013). Hence, patients with schi-
zophrenia prefer non-disclosure to their condition. Non-disclosure, or
maintaining secrecy, may protect them from discrimination, but is as-
sociated with negative long-term outcomes, since the threat of dis-
covery can be a constant stressor (Rusch et al., 2014).
Also, non-disclosure might be a barrier for seeking and receiving
eﬀective treatment. People with schizophrenia might avoid treatment
because of the concern that they will be negatively judged or dis-
criminated by other people, whereas others might avoid addressing
issues related to their disorder because of its potential eﬀect on their
self-esteem, which has already been compromised by internalized
stigma (Lasalvia et al., 2013). Therefore, there is a pressing need to
develop the interventions to support people with mental illness in their
disclosure decisions.
Item 27 in the DISC-12 subscale of overcoming stigma: Have you
been able to use your personal skills in coping with stigma and dis-
crimination? 131 (34.1%) participants answered yes. The result in-
dicated that patients had few skills for coping with stigma, which is
consistent with the previous studies (Carr et al., 2013). A previous study
showed that experienced stigma was associated with more severe de-
pressive symptoms and negative mood, which may aﬀect the use of
speciﬁc coping strategies in people with schizophrenia (Holubova et al.,
2016). Hence, psychiatrists should incorporate coping strategies into
treatment plans for patients to deal with stigma and discrimination.
Indeed our results showed that experienced discrimination had the
strongest association with stigma. So further studies should shift the
focus to discrimination, and campaigns on anti-discrimination should
be initiated.
Since a recent study showed that lower comfort of disclosing one's
mental illness was related to lower well-being (Rusch et al., 2014), we
examined whether experienced discrimination might have impact on
the levels of patients’ quality of life, self-esteem, symptom severity and
psychosocial functioning. We found that the participants had relatively
mild symptoms based on their mean total scores of BPRS and PANSS-N.
This approach targets an important group of patients when evaluating
the long-term management of individuals with schizophrenia and our
sample is likely comparable to stable patients treated in similar settings
in other countries. Our results of SQLS and SES indicated a poor quality
of life and diminished self-esteem in patients with schizophrenia.
The result of the GAF also indicated poor psychosocial function,
according to the category of GAF scores (Link et al., 1997). More psy-
chotic symptoms may also be misunderstood as signs of danger or in-
competence. It is diﬃcult for participants to seek a job. In our study,
more than half of the respondents were unemployed. It's also challen-
ging for participants to communicate with others because many people
in the general public have negative attitudes and perceive people with
schizophrenia as dangerous. In our study, only 38% of the respondents
were married, which is consistent with others (Hopper et al., 2007;
Harangozo et al., 2014) suggesting that many of them had little chance
of having their own family. Our result of multivariable linear regression
indicated that SQLS, SES were main independent determinants of ISMI,
which is consistent with previous studies showing that high levels of
internalized stigma were associated with poorer self-esteem and de-
creased quality of life (Sibitz et al., 2011; Wang et al., 2016).
These results mean that when patients felt misunderstood, separated
and diﬀerent from others, they were angry, embarrassed, ashamed, and
afraid. These negative emotions lead to a feeling of inferiority and
signiﬁcantly inﬂuence the internalization of negative stereotypes,
thereby increasing feelings of stigma and negative consequences.
Furthermore, we also found that patients had better insight and medi-
cation compliance, and insight and medication compliance were highly
correlated in patients with schizophrenia. A possible reason may be that
psychiatric symptoms were controlled by anti-psychotic medications
and patients were willing to adhere to their medications because of a
gradual recovery of insight.
The outcomes we found were enlightened. From the cross-cultural
perspective, Chinese culture was diﬀerent from the Euro-American
culture. The former was mainly aﬀected by Confucianism, while the
latter was impressed by the culture of the ancient Greece and Christian.
Though the culture background was signiﬁcantly diﬀerent, the high
level of stigma patients with schizophrenia experienced was very si-
milar. This revealed a phenomenon that the culture universality was
superior to the culture particularity in the ﬁeld of stigma and dis-
crimination. Furthermore, the ﬁndings in this study were meaningful
for the future interventions. For example, the better outcomes of insight
and medication compliance implicated the importance of medication
management and autonomous control. The poor outcomes of stigma,
social function, quality of life and self-esteem in patients with schizo-
phrenia suggested more trainings, social skills and anti-stigma strate-
gies should be integrated together in the later interventions.
Fortunately, all these approaches are integral and essential components
of our PTSA programme, which hasn’t been completely operated at
present, except the training courses in Guangzhou community-settings
(Li et al., 2014a). Now is good time to ﬁght against stigma and dis-
crimination in LMICs, especially in China.
Several limitations of the study should be taken into consideration.
Firstly, discrimination and stigma are complex concepts inﬂuenced by
multiple factors, which inﬂuence each other. Secondly, assessment of
the factors was performed by the same examiner, which may have in-
creased the interrelationship of the variables. Finally, the data were
collected from a cross-sectional study, and more data will be needed to
fully understand the relationship between these variables. Therefore,
future studies should be conducted in a larger multi-center or multi-
region sample, using cohort study to improve the accuracy and gen-
eralizability of our results in the present study.
In summary, our ﬁndings show that people with schizophrenia
living in the community often experience both stigma and
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discrimination, which are barriers to social participation and successful
vocational integration. Disadvantages such as unemployment and pes-
simistic marriage prospects suggest that it is time to ﬁght against stigma
and discrimination, and interventions are needed to address dis-
crimination and stigma, but also to help service users with speciﬁc
vulnerabilities and concerns regarding discrimination.
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